ArticleNPJ Parkinson's disease2021
Predictors of clinically significant quality of life impairment in Parkinson's disease.
Article in NPJ Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Home physical therapy versus telerehabilitation in improving motor function and quality of life in Parkinson's disease: a randomized controlled trial.BMC geriatrics · 2024Trial
- Online Comprehensive Care Therapy Complementary Program Improves Quality of Life in People with Parkinson's Disease.Brain sciences · 2026Article
- Depression and Mood Changes in People with Parkinson's Disease over Time: A 5-Year Follow-Up Study.Journal of personalized medicine · 2026Article
- Utility of Baseline Pathological, Neuroimaging and Clinical Markers for Prognosis in Early Parkinson's Disease.Journal of geriatric psychiatry and neurology · 2026Article
- Levodopa-entacapone-carbidopa intestinal gel in advanced Parkinson's disease: an analysis of interim data for Romanian patients enrolled in the ELEGANCE study.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Parkinson's disease-subjective cognitive decline and health-related quality of life.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- A narrative review of clinical and non-clinical determinants of health-related quality of life in advanced Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Long term improvement in quality of life in Parkinson's disease after deep brain stimulation of the subthalamic nucleus: an observational cohort.Clinical parkinsonism & related disorders · 2026Article
- Far from being the end of the road: taking a closer look at neuropalliative care in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Assessment of Health-Related Quality of Life in Parkinson's Disease: A Systematic Review.Cureus · 2025Review
- The Multifactorial Memory Questionnaire and Quality of Life: A Longitudinal Study in Parkinson's Disease.Brain sciences · 2025Article
- Review
- Use of the MNCD Classification to Monitor Clinical Stage and Response to Levodopa-Entacapone-Carbidopa Intestinal Gel Infusion in Advanced Parkinson's Disease.Brain sciences · 2024Article
- Article
- Paradigm shift in Parkinson's disease: using continuous telemonitoring to improve symptoms control. Results from a 2-years journey.Frontiers in neurology · 2024Article
- Staging Parkinson's disease according to the MNCD classification correlates with caregiver burden.Brain and behavior · 2023Article
- Sex Differences in Motor and Non-Motor Symptoms among Spanish Patients with Parkinson's Disease.Journal of clinical medicine · 2023Article
- Changes in Principal Caregiver Mood Affects the Mood of the Parkinson's Disease Patient: The Vicious Cycle of Illness.Journal of Parkinson's disease · 2023Article
- Association between inflammatory bowel disease and Parkinson's disease: a prospective cohort study of 468,556 UK biobank participants.Frontiers in aging neuroscience · 2023Article
- Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life.Journal of Parkinson's disease · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
51 authors at 20 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quality of life (QOL) plays an important role in independent living in Parkinson's disease (PD) patients, being crucial to know what factors impact QoL throughout the course of the disease. Here we identified predictors of QoL impairment in PD patients from a Spanish cohort. PD patients recruited from 35 centers of Spain from the COPPADIS cohort from January 2016, to November 2017, were followed up during 2 years. Health-related QoL (HRQoL) and global QoL (GQoL) were assessed with the 39-item Parkinson's disease Questionnaire (PDQ-39) and the EUROHIS-QOL 8-item index (EUROHIS-QOL8), respectively, at baseline (V0) and at 24 months ± 1 month (V2). Clinically significant QoL impairment was defined as presenting an increase (PDQ-39SI) or decrement (EUROHIS-QOL8) at V2 ≥ 10% of the score at baseline (V0). A comparison with a control group was conducted for GQoL. GQoL did not change significantly in PD patients (N = 507; p = 0.686) or in the control group (N = 119; p = 0.192). The mean PDQ-39SI was significantly increased in PD patients (62.7 ± 8.5 years old; 58.8% males; N = 500) by 21.6% (from 16.7 ± 13 to 20.3 ± 16.4; p < 0.0001) at V2. Ninety-three patients (18.6%) presented a clinically significant HRQoL impairment at V2. To be younger (OR = 0.896; 95% CI 0.829-0.968; p = 0.006), to be a female (OR = 4.181; 95% CI 1.422-12.290; p = 0.009), and to have a greater increase in BDI-II (Beck Depression Inventory-II) (OR = 1.139; 95% CI 1.053-1.231; p = 0.001) and NMSS (Non-Motor Symptoms Scale) (OR = 1.052; 95% CI 1.027-1.113; p < 0.0001) total scores from V0 to V2 were associated with clinically significant HRQoL impairment at the 2-year follow-up (Hosmer-Lemeshow test, p = 0.665; R
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.